濮阳东方医院看男科技术很专业(濮阳东方医院男科治早泄评价非常高) (今日更新中)

TIANJIN, April 16 (Xinhua) -- As China tries to establish a universal medicare umbrella, its first move to offer treatment to all the hemophilia patients in the country is to know their population and where they are.China's national hemophilia information management center registered 7,980 cases nationwide since its establishment last year in a bid to provide reference for making national treatment policies and medicine production quota, said the center officials Saturday.Yang Renchi with the center and the Chinese Academy of Medical Sciences, said that the patient information database will help the government make hemophilia-related medical and social welfare policies, optimize resources and guide the manufacturing of drugs such as coagulation factor VIII.The information center, created by the Ministry of Health, is located in the Blood Diseases Hospital of the Chinese Academy of Medical Sciences in the port city Tianjin in north China.Hemophilia is a rare genetic bleeding disorder that prevents the blood from clotting properly, resulting in easy bruising and prolonged bleeding from trauma. Lack of treatment can lead to permanent disabilities or even death.China is estimated to have roughly 100,000 hemophilia patients."Be inspired; get involved in Treatment for All" is the theme for the 22nd World Hemophilia Day, which falls on Sunday, April 17."A necessary precondition for 'Treatment for All' is to know the clinical information and location of each case," said Yang, "and this is exactly what the information system does."In addition, China plans to establish hospital-based provincial hemophilia management centers within five years across the country to register and monitor patients and standardize disease diagnosis and treatment under the information system.SHORTAGE OF DRUGSBlood-derived coagulation factor VIII and recombinant coagulation factor VIII are two effective drugs which are vital for hemophiliacs. However, the drugs are expensive and produced in limited quantities, a difficulty which hundreds of thousands of hemophiliacs in China have to confront.According to Yang, the minimum dose of coagulation factor VIII for prevention of bleeding episodes is two international units (IU) per kg of weight a day. A 50-kg hemophilia patient needs at least 36,500 IU of factor VIII every year to prevent bleeding."Each IU of blood-derived coagulation factor VIII costs about 3 yuan(0.46 U.S. dollars) and the annual cost is almost 120,000 yuan. The recombinant one is almost twice the price," said Yang.Only four drug firms are qualified to manufacture blood-derived coagulation factor VIII in China. The national output in 2010 was 400,000 vials (200 IU per vial) which means 80 million IU for the entire country.Wu Runhui, a hematology specialist with the Beijing Children's Hospital, said that the minimum dose is only for the prevention of bleeding episodes which are required to keep the patient alive. For the hemophiliac to live a regular lifestyle, 3,000 IU per kilo a year is needed, which would cost half a million yuan a year."Even in the most developed countries, a hemophiliac cannot survive without supportive medical policies and social welfare system," said Wu.

CAIRO, Jan. 23 (Xinhua) -- The first training session for Egyptian Chinese language teachers to improve their teaching ability started on Sunday in Cairo.The session, under the supervision of the Chinese Confucius institute, will concentrate on the exchange of experiences in teaching the Chinese language in Egypt and the enhancement of Egyptian teachers' ability to make better use of the textbooks.The three-day training session will contain language and cultural courses by professors and instructors from famous Chinese universities such as Beijing University and Beijing Foreign Studies University, said Li Shengjun, head of the Confucius Institute at Cairo University.Nearly 60 Egyptian Chinese language teachers, including 14 professors, from universities including Cairo University, Ain Shams University and Minya University will attend the training courses.China has established 691 Confucius institutes and classes in around 69 countries until 2010, including nine in the Arab countries.

WASHINGTON, March 22 (Xinhua) -- A long-term study by Greek researchers has shown the effectiveness of replacing bone marrow, purposely destroyed by chemotherapy, with autologous (self) stem cells in treating people with aggressive forms of multiple sclerosis (MS).The study was published on Tuesday in Neurology, the medical journal of the American Academy of Neurology.For the treatment, chemotherapy drugs are used to kill all of the patient's blood cells, including the immune cells that are believed to be attacking the body's own central nervous system. Bone marrow stem cells removed from the patient are purified and transplanted back into the body, which saves life by replacing the blood cells and also is proposed to "reboot" the immune system.A human embryonic stem cell line derived at Stanford University is seen in this handout photo released to Reuters by the California Institute for Regenerative Medicine, March 9, 2009The study followed 35 people for an average of 11 years after transplant. The study involved people with rapidly progressive MS who had tried a number of other treatments for MS with little or no effect. All were severely disabled by the disease, with an average score of six on a scale of disease activity that ranges from zero being a normal neurological examination to 10 meaning death due to MS.A score of six means able to walk with a cane or crutch; a seven is mainly in a wheelchair. All had worsened by at least one point on the scale in the year prior to the transplant.After the transplants, the probability of participants having no worsening of their disease for 15 years was 25 percent. The probability was higher -- 44 percent -- for those who had active brain lesions, which are a sign of disease activity, at the time of the transplant.For 16 people, symptoms improved by an average of one point on the scale after the transplant, and the improvements lasted for an average of two years. The participants also had a reduction in the number and size of lesions in their brains. Two people (six percent) died from complications related to the transplant at two months and 2-1/2 years post-transplant.Study author Vasilios Kimiskidis, of Aristotle University in Thessaloniki, Greece, noted that more research is needed on this treatment, including studies that compare people receiving the treatment to a control group that does not receive the treatment."Keeping that in mind, our feeling is that stem cell transplants may benefit people with rapidly progressive MS," he said. "This is not a therapy for the general population of people with MS but should be reserved for aggressive cases that are still in the inflammatory phase of the disease."

BEIJING, May 19 (Xinhuanet) -- LinkedIn said Wednesday that its stock will debut at 45 U.S. dollars per share, a higher price than the company was expecting even earlier this week, media reports said.The first major U.S. social networking firm to go public, LinkedIn jacked up its initial public offering (IPO) share price for 7.84 million shares to 45 dollars just a week after it first set a target of 32-35 dollars per share.It minted LinkedIn with a market value of more than 4 billion dollars, the highest for a U.S. Internet company taking its first bow on Wall Street since Google Inc. went public nearly seven years ago.The sale could bring in more than 354 million dollars. The company's shares are expected to begin trading on the New York Stock Exchange on Thursday under the symbol "LNKD".LinkedIn has more than 100 million members in over 200 countries and territories. In 2010, the company made 15 million dollars in profit on 243 million dollars in revenue, according to its SEC filing.LinkedIn's biggest shareholder is its founder and chairman, Reid Hoffman, who owns more than 21 percent of the company.

GENEVA, May 3 (Xinhua) -- Roughly half to three quarters of adults aged between 18 to 65 years have had headache in the last year, a prevalent problem that went under-treated, the Geneva based World Health Organization (WHO) said in a report issued Tuesday.The report, named "Of Headache Disorders and Resources in the World 2011," regarded headache disorders as one of the most prevalent disorders of mankind.WHO estimated over 10 percent of the adult population suffered from migraine, and 1.7 to 4 percent of them were troubled frequently by headache on 15 or more days every month.Among all cases studied, the report said, on average only 10 percent were treated by neurologists, and the rates were even lower in Africa and South-East Asia.Three types of headache disorders were underlined as the most frequently seen, including migraine, tension-type headache and that caused by medication-overuse.The report concluded that given the very high indirect costs of headache, investment in health care related to headache treatment might be overall cost-saving to society.

来源：资阳报